ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

Post-LOE

ipratropium bromide and albuterol sulfate

Nephron Pharmaceuticals

ANDAINHALATIONSOLUTION

Approved

Oct 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE (ipratropium bromide and albuterol sulfate) by Nephron Pharmaceuticals is mechanism of action the prime action of β-adrenergic drugs is to stimulate adenyl cyclase, the enzyme that catalyzes the formation of cyclic-3',5'-adenosine monophosphate (camp) from adenosine triphosphate (atp). Approved for bronchospasm associated with copd in patients requiring more than one bronchodilator, copd. First approved in 2012.

Drug data last refreshed 1w ago

Mechanism of Action

Mechanism of Action The prime action of β-adrenergic drugs is to stimulate adenyl cyclase, the enzyme that catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). The cAMP thus formed mediates the cellular responses. In vitro studies and in vivo…

Indications (2)

bronchospasm associated with COPD in patients requiring more than one bronchodilator

Worked on ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE at Nephron Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.